trending Market Intelligence /marketintelligence/en/news-insights/trending/dMC08jcTb_WMBn8RB3uEOQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Innate Pharma blood cancer drug accepted for EU review

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Innate Pharma blood cancer drug accepted for EU review

Innate Pharma SA said the European Medicines Agency accepted its application seeking approval for its blood cancer treatment Lumoxiti.

The Marseille, France-based drugmaker is seeking approval for Lumoxiti to treat adults with hairy cell leukemia who have received at least two prior systemic therapies — including a purine nucleoside analog — but whose disease returned or did not respond to existing treatment.

Hairy cell leukemia is a rare, chronic and slow-growing leukemia in which the bone marrow overproduces abnormal B cell lymphocytes, a type of white blood cell.

The filing is based on the results of a late stage trial of Lumoxiti, or moxetumomab pasudotox-tdfk, which showed the medicine benefited patients. Innate licensed Lumoxiti from AstraZeneca PLC in October 2018.

The U.S. Food and Drug Administration approved Lumoxiti in September 2018 under its priority review process.